Skip to main content
. 2024 Apr 23;7:489. doi: 10.1038/s42003-024-06121-9

Table 4.

Approved CRISPR-based medicine

Trade name (drug name) Approval year Strategy Targeted gene Disease Company
Casgevy™ (Exagamglogene autotemcel) 2023 Ex vivo-Autologous transfusion BCL11A β-thalassemia Sickle Cell Disease Vertex Pharmaceutical